The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018

New data on cardiovascular effects of long-term Brilinta use in patients with a history of heart attack

Data from 20 abstracts further highlight AstraZeneca’s holistic approach to care in cardiovascular, renal and metabolic diseases

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular (CV) outcomes trial (CVOT) DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the American Heart Association (AHA) Scientific Sessions, 10-12 November 2018, in Chicago, Illinois, USA.

New evidence will build on broad clinical research from AstraZeneca that aims to help redefine the management of CVRM diseases and address the need for a more proactive and holistic approach to patient care. Presentations will include findings from some of the largest trials in broad patient populations with Farxiga (dapagliflozin) in type-2 diabetes (T2D), Brilinta (ticagrelor) in patients with a history of heart attack, and in hyperkalaemia.

Danilo Verge, Vice President, Cardiovascular, Renal & Metabolism, Global Medical Affairs, said: “An estimated 20 million people each year die from cardiovascular, renal and metabolic diseases, yet shared risk factors are frequently not diagnosed or addressed holistically. Our data at AHA reflect an integrated approach to managing the needs of patients living with type-2 diabetes and risk of cardiovascular or renal disease, and those with a history of cardiovascular disease at acute and long-term risk of recurrence. We stand firmly behind our mission to provide new solutions earlier in disease management to these patients at risk for multiple complications.”

DECLARE-TIMI 58: a landmark CVOT evaluating CV risk in patients with T2D

Clinical trial results showing the safety and efficacy of Farxiga vs. placebo on primary CV and secondary renal efficacy outcomes in adults with T2D who have multiple CV risk factors or established CV disease, will be presented in a late-breaking oral presentation (Late Breaking Abstract #19485). DECLARE-TIMI 58 evaluated the CV outcomes of Farxiga vs. placebo over a period of up to five years, across 33 countries and in more than 17,000 adults with T2D with multiple CV risk factors or established CV disease.

In September 2018, AstraZeneca announced that Farxiga met its primary safety endpoint of non-inferiority for major adverse cardiovascular events (MACE) and achieved a statistically-significant reduction in the composite endpoint of hospitalisation for heart failure (hHF) or CV death, one of the two primary efficacy endpoints. Additionally, fewer MACE events were observed with Farxiga for the other primary efficacy endpoint, however, this did not reach statistical significance. Clinical trial results presented at AHA Scientific Sessions 2018 will include additional details on the primary CV safety and efficacy, as well as secondary renal efficacy outcomes from DECLARE-TIMI 58.

Three new sub-analyses from the PEGASUS-TIMI 54 trial will also be presented. The trial compared Brilinta (90mg or 60mg twice daily) plus aspirin vs. aspirin alone in 21,162 patients with prior (1 to 3 years) heart attack. The sub-analyses evaluate:

  • Whether clinical characteristics predicting bleeding and ischaemic risk identify subgroups of patients who may derive benefit from long-term treatment with Brilinta, with a lower risk of major bleeding (Poster #Sa2100)
  • The effects of long-term use of Brilinta in patients who have had a heart attack and who did not receive a coronary stent vs. those who did receive a coronary stent placement (Oral Presentation #102)
  • The use of high-sensitivity cardiac troponin to identify patients who are at a higher-risk of major cardiovascular events (Oral Presentation #100)

Data will also be presented on potential risk factors for repeated or persistent hyperkalaemia (Poster # SuMDP65).

Key abstracts at the AHA Scientific Sessions 2018:

Abstract title Presentation details
The Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial Late Breaking Abstract #19485Saturday Nov 10, 3:45 PM - 4:00 PMSession: LBS.02. Late Breaking Clinical Trial: Novel Approaches to CV Prevention

Long-Term Secondary Prevention with Ticagrelor for Prior Myocardial Infarction in Patients with no Coronary Stenting: A Sub-analysis from PEGASUS TIMI 54 Oral Presentation #102
Sunday November 11, 4:15 PM - 4:25 PM
Session: AC.AOS.01, S103bc. Advances in the Prediction and Modification of Cardiovascular Disease Risk
High-sensitivity Cardiac Troponin at Any Detectable Concentration Identifies Higher Risk of Major Cardiovascular Events in Patients with Stable Ischemic Heart Disease Oral Presentation #100November 11, 3:45 PM - 3:55 PMSession: AC.AOS.01, S103bc. Advances in the Prediction and Modification of Cardiovascular Disease Risk
Method of Assessing Medication Persistence and Clinical Outcomes: A Comparison of Patient Report and Pharmacy Fill Data from the ARTEMIS Trial Oral Presentation #452November 11, 2:45 PM - 2:50 PMSession: QU.RFO1. ACS Top QCOR Abstracts: Rapid Fire
Impact of Coronary Artery Disease Severity on Risk of Cardiovascular Disease in Type 2 Diabetes Patients: A Swedish Nationwide Observational Study Poster # Su1297, 1297November 11, 10:30 AM - 11:45 AM Session: QU.APS.03. Acute and Chronic Coronary Artery Disease: Quality Care and Outcomes
Patient Selection for Long-Term Prevention of Limb Ischemic Events Oral Presentation (Rapid Fire) #419November 10, 2:15 PM - 3:30 PMSession: VA.RFO1. Understanding Risk and Mechanisms of Critical Limb Ischemia: Lessons from the Long CLImb
Patient Selection for Long-Term Secondary Prevention with Ticagrelor: Insights from PEGASUS-TIMI 54 Poster #Sa2100, 2100November 10, 2:15 PM - 3:30 PMSession: AC.APS.09. Pharmacotherapy in ACS and Stable Ischemic Heart Disease
Caffeine and Dyspnea With Ticagrelor: A Sub-analysis From PEGASUS TIMI-54 Trial Poster #2097, Sa2097November 10, 2:15 PM - 3:30 PMSession: AC.APS.09. Pharmacotherapy in ACS and Stable Ischemic Heart Disease
The 'Halo Effect" of a P2Y12 Inhibitor Copayment Reduction Intervention on Adherence and Persistence with other Cardiovascular medications: Results from the ARTEMIS Cluster Randomized Trial Poster #Sa2098, 2098November 10, 2:15 PM - 3:30 PMSession: AC.APS.09. Pharmacotherapy in ACS and Stable Ischemic Heart Disease

What Characterizes the Patients who Develop Repeated or Persistent Hyperkalaemia? Poster # SuMDP65November 11, 11:45 AM - 12:55 PMSession: HF.MDP2. Interesting Topics in Heart Failure and Cardiomyopathy

The full list of scientific data can be accessed on the AHA 2018 Online Planner here. You can also follow us live during the event on Twitter and LinkedIn.

– ENDS –


About AstraZeneca in Cardiovascular, Renal & Metabolism (CVRM)

Cardiovascular, renal and metabolism together form one of AstraZeneca’s main therapy areas and a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit and follow us on Twitter @AstraZeneca.

Media Relations 
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906 
Gonzalo Viña   UK/Global  +44 203 749 5916 
Jennifer Hursit UK/Global +44 203 749 5762 
Jacob Lund Sweden +46 8 553 260 20 
Michele Meixell US +1 302 885 26 77
 Investor Relations 
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Cardiovascular; Metabolism +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors +44 203 749 5824
US toll-free +1 866 381 7277

Om oss

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre huvudsakliga terapiområden: cancer, kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar och sjukdomar i andningsvägarna. Bolaget är också selektivt aktivt inom autoimmunitet, neurovetenskap och infektion. AstraZeneca bedriver verksamhet i över 100 länder och dess innovativa läkemedel används av miljontals patienter över hela världen. Mer information finns på: och